Biohaven Ltd.
General ticker "BHVN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.3B (TTM average)
Biohaven Ltd. does not follow the US Stock Market performance with the rate: -3.2%.
Estimated limits based on current volatility of 3.0%: low 8.57$, high 9.46$
Factors to consider:
- Total employees count: 30000 (+3132.8%) as of 2022
- Top business risk factors: Inability to raise capital, Liquidity and credit risks, Dependence on limited products, System failures and security breaches, Volatility in common share prices
- Current price 43.6% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [17.05$, 44.05$]
- 2025-12-31 to 2026-12-31 estimated range: [11.02$, 29.50$]
Financial Metrics affecting the BHVN estimates:
- Negative: with PPE of -3.9 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -17.64 <= 0.33
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Investing cash flow per share per price, % of -7.42 <= -4.48
Short-term BHVN quotes
Long-term BHVN plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $567.93MM | $436.05MM | $885.11MM |
| Operating Income | $-567.93MM | $-436.05MM | $-885.11MM |
| Non-Operating Income | $-1.91MM | $26.50MM | $39.42MM |
| R&D Expense | $437.07MM | $373.28MM | $795.87MM |
| Income(Loss) | $-569.84MM | $-409.55MM | $-845.69MM |
| Taxes | $0.44MM | $-1.38MM | $0.73MM |
| Profit(Loss)* | $-570.28MM | $-408.17MM | $-846.42MM |
| Stockholders Equity | $538.77MM | $427.98MM | $423.44MM |
| Assets | $661.78MM | $513.21MM | $615.11MM |
| Operating Cash Flow | $-297.69MM | $-331.73MM | $-582.45MM |
| Capital expenditure | $41.07MM | $3.05MM | $4.05MM |
| Investing Cash Flow | $-304.79MM | $129.83MM | $-244.97MM |
| Financing Cash Flow | $767.60MM | $211.91MM | $677.77MM |
| Earnings Per Share** | $-12.75 | $-5.73 | $-9.28 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.